文献速递肝肾功能剂量调整治疗药物监测与药物基因组学特殊人群用药

危重症成人CRRT患者万古霉素药代动力学与给药范围综述

Vancomycin pharmacokinetics and dosing in critically ill adult patients on continuous renal replacement therapy: A scoping review.
PubMed 文献 · Am J Health Syst Pharm · 2026-08-27

该范围综述检索截至2026年4月的文献,纳入24项研究,评估接受连续性肾脏替代治疗(CRRT)的危重症成人万古霉素药代动力学与给药。万古霉素总清除率1.5–4.8 L/h,CRRT占至少50%且受模式与强度影响,分布容积0.4–1.4 L/kg,个体间变异大,模拟支持模型引导精准给药。

要点

  • CRRT危重症成人万古霉素总清除率1.5–4.8 L/h,CRRT占至少50%。
  • 分布容积0.4–1.4 L/kg,群体药代动力学显示个体间变异大。
  • 模拟研究支持负荷15–30 mg/kg、维持5–20 mg/kg每日的模型引导给药。

核心结论

  • CRRT危重症成人万古霉素药代动力学显著改变,给药需个体化并结合治疗药物监测与模型引导方法。
  • 未来研究应验证个体化给药策略并将药代动力学/药效学靶标与临床结局关联。

研究设计与样本

  • 遵循PRISMA-ScR指南的系统范围综述,检索Ovid MEDLINE via PubMed、Cochrane Central Register of Controlled Trials和ClinicalTrials.gov,截至2026年4月。
  • 检索获得114项研究,最终纳入24项英文研究,对象为接受CRRT的危重症成人,采用单剂或多剂群体药代动力学评估万古霉素药代动力学与给药。

主要发现

  • 万古霉素总清除率范围为1.5–4.8 L/h,持续受CRRT影响。
  • CRRT占万古霉素总清除率至少50%,CRRT模式和强度是关键决定因素。
  • 万古霉素分布容积在0.4–1.4 L/kg范围内变化。
  • 群体药代动力学研究显示高个体间变异,剂量模拟研究支持模型引导精准给药。
  • 模拟研究报告负荷剂量范围15–30 mg/kg,维持剂量范围5–20 mg/kg每日。

关键数值与推荐

  • 纳入标准:英文研究、危重症成人CRRT患者、采用单剂或多剂群体药代动力学评估万古霉素药代动力学与给药。
  • 模拟研究支持负荷剂量15–30 mg/kg和维持剂量5–20 mg/kg每日的范围。

临床怎么用

  • CRRT危重症成人万古霉素给药应个体化,考虑CRRT模式和强度对清除率的显著影响。
  • 建议开展治疗药物监测并采用模型引导精准给药以应对高个体间变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Acute kidney injury is common in critically ill patients, frequently requiring the use of continuous renal replacement therapy (CRRT). Both critical illness and CRRT significantly alter vancomycin pharmacokinetics, affecting dosing and therapeutic drug monitoring. This scoping review aimed to evaluate vancomycin pharmacokinetics and dosing in critically ill adults receiving CRRT. SUMMARY: A systematic scoping review was conducted using PRISMA-ScR guidelines. Studies published through April 2026 were identified using a comprehensive search of Ovid MEDLINE via PubMed, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. Included studies were in English, involved critically ill adult patients on CRRT, and assessed vancomycin pharmacokinetics and dosing using single- or multiple-dose population pharmacokinetics. Authors screened studies using a standard form, and disagreements were resolved through consensus. The searches retrieved 114 studies, and 24 were included. Vancomycin total clearance (CL) ranged from 1.5 to 4.8 L/h and was consistently influenced by CRRT. CRRT accounted for at least 50% of total CL, with CRRT modality and intensity being key determinants. Vancomycin's volume of distribution varied within a range of 0.4 to 1.4 L/kg. Population pharmacokinetic studies showed high interindividual variability, and dose simulation studies supported model-informed precision dosing. Simulation studies reported loading and maintenance dose ranges of 15-30 mg/kg and 5-20 mg/kg daily, respectively. CONCLUSION: Vancomycin dosing in patients on CRRT is highly variable due to significant pharmacokinetic alterations, emphasizing the need for individualized dosing, therapeutic drug monitoring, and model-informed approaches. Future studies should focus on validating personalized dosing strategies and linking pharmacokinetic/pharmacodynamic targets with clinical outcomes in this population.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Assadoon MS, Pearson JC, Alzaidi SH, et al. Vancomycin pharmacokinetics and dosing in critically ill adult patients on continuous renal replacement therapy: A scoping review. Am J Health Syst Pharm. 2026. PMID: 42659642. doi:10.1093/ajhp/zxag257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。